BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18250227)

  • 1. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.
    Kiladjian JJ; Cervantes F; Leebeek FW; Marzac C; Cassinat B; Chevret S; Cazals-Hatem D; Plessier A; Garcia-Pagan JC; Darwish Murad S; Raffa S; Janssen HL; Gardin C; Cereja S; Tonetti C; Giraudier S; Condat B; Casadevall N; Fenaux P; Valla DC
    Blood; 2008 May; 111(10):4922-9. PubMed ID: 18250227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
    Magaz M; Alvarez-Larrán A; Colomer D; López-Guerra M; García-Criado MÁ; Mezzano G; Belmonte E; Olivas P; Soy G; Cervantes F; Darnell A; Ferrusquía-Acosta J; Baiges A; Turon F; Hernández-Gea V; García-Pagán JC
    J Hepatol; 2021 Jan; 74(1):89-95. PubMed ID: 32679300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.
    Smalberg JH; Arends LR; Valla DC; Kiladjian JJ; Janssen HL; Leebeek FW
    Blood; 2012 Dec; 120(25):4921-8. PubMed ID: 23043069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
    De Stefano V; Qi X; Betti S; Rossi E
    Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
    Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
    Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F].
    Fama A; Rago A; Gioiosa F; Marzano C; Latagliata R; Mammì C; Laganà C; D'Elia GM; Bizzoni L; Trasarti S; Ferretti A; Breccia M; Riggio O; Tafuri A
    Clin Ter; 2010; 161(2):169-71. PubMed ID: 20499034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2V617F mutation in patients with splanchnic vein thrombosis.
    Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
    Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 mutations across a spectrum of venous thrombosis cases.
    Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
    Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study.
    Fan J; Wang Q; Luo B; Chen H; Wang Z; Niu J; Yuan J; Yuan X; Bai W; He C; Guo W; Li K; Yin Z; Fan D; Han G
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1215-1222. PubMed ID: 31711259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
    Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
    Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.
    Qi X; Yang Z; Bai M; Shi X; Han G; Fan D
    Aliment Pharmacol Ther; 2011 May; 33(10):1087-103. PubMed ID: 21395632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.
    Brière JB
    Semin Thromb Hemost; 2006 Apr; 32(3):208-18. PubMed ID: 16673275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
    Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
    Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.
    Poisson J; Plessier A; Kiladjian JJ; Turon F; Cassinat B; Andreoli A; De Raucourt E; Goria O; Zekrini K; Bureau C; Lorre F; Cervantes F; Colomer D; Durand F; Garcia-Pagan JC; Casadevall N; Valla DC; Rautou PE; Marzac C;
    J Hepatol; 2017 Sep; 67(3):501-507. PubMed ID: 28483676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
    Patel RK; Lea NC; Heneghan MA; Westwood NB; Milojkovic D; Thanigaikumar M; Yallop D; Arya R; Pagliuca A; Gäken J; Wendon J; Heaton ND; Mufti GJ
    Gastroenterology; 2006 Jun; 130(7):2031-8. PubMed ID: 16762626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study.
    Qi X; Zhang C; Han G; Zhang W; He C; Yin Z; Liu Z; Bai W; Li R; Bai M; Yang Z; Wu K; Fan D
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1036-43. PubMed ID: 22142461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective.
    Pescia C; Lopez G; Cattaneo D; Bucelli C; Gianelli U; Iurlo A
    Leuk Res; 2024 Jan; 136():107420. PubMed ID: 38016412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis.
    Li M; De Stefano V; Song T; Zhou X; Guo Z; Zhu J; Qi X
    Thromb Res; 2018 Jul; 167():96-103. PubMed ID: 29803161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.